Dennis Cho Sells 277 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 277 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $11,332.07. Following the transaction, the insider now owns 111,984 shares in the company, valued at $4,581,265.44. The trade was a 0.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Dennis Cho also recently made the following trade(s):

• On Monday, February 3rd, Dennis Cho sold 806 shares of Twist Bioscience stock. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10.
• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total value of $6,225.73.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded down $2.72 during mid-day trading on Monday, hitting $36.71. 1,733,475 shares of the stock were exchanged, compared to its average volume of 982,978. The company has a 50-day simple moving average of $46.54 and a 200 day simple moving average of $45.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $2.19 billion, a P/E ratio of -10.86 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the firm earned ($0.75) EPS. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. Sell-side analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Trading of Twist Bioscience

Several hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the third quarter worth about $34,000. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the period. Banque Transatlantique SA purchased a new position in Twist Bioscience in the 4th quarter valued at approximately $43,000. GF Fund Management CO. LTD. bought a new stake in Twist Bioscience during the 4th quarter valued at $58,000. Finally, US Bancorp DE lifted its position in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after acquiring an additional 601 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Barclays set a $58.00 price target on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.